Lexicon Pharmaceuticals, Inc. (LXRX) Stock
Key stats
- Market cap
- $832.59M
- Price / Earnings ratio
- -13.3x
- EPS (TTM)
- -$0.14
- Volume
- Loading
- 52-week high
- $2.68
- 52-week low
- $1.10
Source: third-party data provider, as of November 13, 2026
Compare with LXRX
Recent news
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
LXRX
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
LXRX
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
LXRXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.84
- MACD 12/26/9
- 0.00
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.07
- SMA 50
- $1.79
- Price above SMA 50
- EMA 50
- $1.77
- Price above EMA 50
- SMA 200
- $1.89
- Price below SMA 200
- EMA 200
- $1.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
LXRXLexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
LXRXLXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRXLexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
LXRX
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
LXRX
Here's Why You Should Add LXRX Stock to Your Portfolio Now
Here's Why You Should Add LXRX Stock to Your Portfolio Now
LXRX
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
LXRX
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
LXRX
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
LXRX
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
LXRXNews tone: automated (AI) classification of the article's content, not a price prediction.
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael S. Exton Ph.D. | CEO & Director | 1970 |
| Mr. Scott M. Coiante | Senior VP & CFO | 1967 |
| Mr. Brian T. Crum | Senior VP, General Counsel & Secretary | 1973 |
| Ms. Wendy E. McDermott | Senior Vice President of Human Resources | 1971 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior VP & Chief Medical Officer | 1965 |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | 1968 |
| Ms. Lisa M. DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 1980 |
| Dr. Suma Gopinathan M.S., Ph.D. | Senior Vice President of Discovery | 1973 |
| Ms. Rachel Yap Martens | Senior VP & Chief Commercial Officer | 1984 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.84
- MACD 12/26/9
- 0.00
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.07
- SMA 50
- $1.79
- Price above SMA 50
- EMA 50
- $1.77
- Price above EMA 50
- SMA 200
- $1.89
- Price below SMA 200
- EMA 200
- $1.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $3.40
- Average
- $5.70
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.1 | -14.0 | ||||||||||
| 2022 | -18.5 | -36.9 | -0.9 | -19.6 | -8.3 | +6.3 | +22.7 | +16.0 | -13.0 | -12.2 | -3.6 | -10.7 |
| 2023 | +12.6 | -0.9 | +10.5 | -2.8 | +35.2 | -15.5 | -13.4 | -11.3 | -35.5 | +21.6 | -20.9 | +33.0 |
| 2024 | +17.6 | +25.8 | -3.2 | -32.5 | +3.0 | -4.0 | +17.9 | |||||
| 2026 | +36.3 | +15.9 | -1.3 | -3.4 | -14.2 | -22.0 | +29.2 |
